Evidence map›Paper›PMID 21988716›Full record

ArticleTissue engineering. Part A2012

Effects of glucocorticoid receptor small interfering RNA delivered using poly lactic-co-glycolic acid microparticles on proliferation and differentiation capabilities of human mesenchymal stromal cells.

Liu Hong, Na Wei, Vijaya Joshi, Yang Yu, NaJung Kim, Yogita Krishnamachari, Qiang Zhang, Aliasger K Salem

Abstract read
In one paragraph

Article in Tissue engineering. Part A, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Applications of nanotechnology in 3D printed tissue engineering scaffolds.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Gene therapy for bone engineering.Frontiers in bioengineering and biotechnology · 2015
    Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Liu HongDows Institute for Dental Research, College of Dentistry, University of Iowa, Iowa City, Iowa 52242, USA. liu-hong@uiowa.edu
Na Wei
Vijaya Joshi
Yang Yu
NaJung Kim
Yogita Krishnamachari
Qiang Zhang
Aliasger K Salem
University of Iowa · USShenzhen Maternity and Child Healthcare Hospital · CN

Funding

Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Brandi Janssen · 1990 to 2026
$40.5M
Engineered Optimal Adjuvant and Antigen Release from Biodegradable NanoparticlesR21CA128414 · NCI · UNIVERSITY OF IOWA · PI SALEM, ALIASGER K · 2009 to 2010
$264k
NCI NIH HHS 1R21CA128414-01A2NCI NIH HHS 1R21CA13345-01NIEHS NIH HHS P30 ES005605
6 · The paper itself

Abstract

Bone marrow-derived mesenchymal stem cells (MSC) are a potential attractive source of cells for stem cell-based tissue regeneration, but the small number and reduced capabilities of MSC proliferation and differentiation due to in vitro replicative senescence and donor-associated pathophysiological factors, including age and estrogen depletion, severely restrict their potential usefulness in clinical applications. Glucocorticoids (GC) are well-known steroid hormones that regulate MSC proliferation and differentiation, but the defined effects and underlying mechanisms of endogenous glucocorticoids on MSC characteristics are not understood. This study investigated the effects of the blockage of endogenous GC using glucocorticoid receptor (GR) small interfering RNA (siRNA) delivered using biodegradable poly(lactic-co-glycolic acid) (PLGA) microparticles on proliferation and differentiation capabilities of human MSC in vitro. The results show that we can prepare PLGA microparticles as a delivery system for GR siRNA and maintain release of siRNA up to 40 days in vitro. Transfection of GR siRNA significantly downregulates GR and upregulates the expression of fibroblast growth factor-2 and Sox-11 of human MSC. MSC that have proliferated with endogenous GC blocked in vitro have greater proliferation rates and exhibit upregulated expression of osteogenic markers (alkaline phosphatase and core binding factor alpha 1) under differentiation stimulation after 1 week. Under adipogenic differentiation, MSC proliferated in vitro with siRNA transfection, resulting in significantly lower adipogenic markers (peroxisome proliferator-activated receptor and lipoprotein lipase) than controls. In conclusion, PLGA particles can serve as a tool for delivery of GR siRNA to effectively block the effects of endogenous GC on MSC, which has the potential to improve the capabilities of human MSC for clinical application by preventing replicative senescence.

Indexed as

Cell DifferentiationCells, CulturedHumansLactic AcidMesenchymal Stem CellsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerReceptors, GlucocorticoidRNA, Small InterferingLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerReceptors, GlucocorticoidRNA, Small Interfering

Identifiers

PMID21988716
PMCPMC3313605
OpenAlexW2093104006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.